Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | KDM6A | O15550 | 1/20 | 0.45 |
| ▸ | KDM4A | O75164 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | KDM5C | P41229 | 1/20 | 0.45 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.45 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.45 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.45 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | NNMT | P40261 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4562515 | 0.80 | NOTUM (0.55) | KDM4EKDM6AKDM4ACYP2C9CYP2C19 | |
| SCHEMBL16217227 | 0.79 | KDM4E (0.42) | KDM4EKDM6AKDM4ACYP2C9CYP2C19 | |
| SCHEMBL25072434 | 0.78 | KDM4E (0.35) | KDM4EKDM6AKDM4ACYP2C9CYP2C19 | |
| Hydrochloric Acid SCHEMBL30678145 | 0.78 | NOTUM (0.53) | KDM4EKDM6AKDM4ACYP2C9CYP2C19 | |
| SCHEMBL28202433 | 0.78 | SIRT3 (0.38) | KDM4ESIRT3TDP1NOTUMMAPT | |
| SCHEMBL19651995 | 0.78 | SIRT3 (0.39) | KDM4EKDM6AKDM4ACYP2C9CYP2C19 | |
| SCHEMBL9736660 | 0.77 | CYP2C19 (0.44) | KDM4EKDM6AKDM4ACYP2C9CYP2C19 | |
| SCHEMBL16418351 | 0.75 | KDM4E (0.46) | KDM4EKDM6AKDM4ACYP2C9CYP2C19 | |
| SCHEMBL16417043 | 0.75 | BRD4 (0.45) | KDM4EKDM6AKDM4ACYP2C9CYP2C19 | |
| SCHEMBL31748394 | 0.74 | KDM4E (0.55) | KDM4EKDM6AKDM4ACYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109320499-A | Pyrrole-3-carboxamide class compound and its preparation method and application | 沈阳药科大学 | 2019-02-12 | — | — | CN | claimed |
| JP-4703649-B2 | — | — | 2011-06-15 | — | — | JP | claimed |
| EP-1773768-A4 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2008-08-06 | — | — | EP | claimed |
| EP-1773768-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | Exelixis, Inc. (US) | 2007-04-18 | — | — | EP | claimed |
| WO-2006012642-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS, INC. (US) | 2006-02-02 | — | — | WO | claimed |
| WO-2025233641-A1 | NOVEL PHOTOINDUCIBLE KINASE INHIBITORS FOR TREATING PROLIFERATIVE AND VASOPROLIFERATIVE DISEASES | SEMMELWEIS EGYETEM (HU) | 2025-11-13 | — | — | WO | disclosed |
| US-20250115577-A1 | BCL-2 Inhibitors | Eil Therapeutics, Inc. | 2025-04-10 | — | — | US | disclosed |
| CN-119053587-A | 5- [7- (3, 4-Dihydro-1H-isoquinoline-2-carbonyl) -1,2,3,4 tetrahydroisoquinolin-6-yl ] -1H-pyrrole-3-carboxamide derivatives, pharmaceutical compositions containing same and use thereof as pro-apoptotic agents | 法国施维雅药厂 | 2024-11-29 | — | — | CN | disclosed |
| EP-4457223-A1 | BCL-2 INHIBITORS | Eil Therapeutics, Inc. (US) | 2024-11-06 | — | — | EP | disclosed |
| CN-118451070-A | BCL-2 inhibitors | 伊尔治疗学股份有限公司 | 2024-08-06 | — | — | CN | disclosed |
| US-12053465-B2 | KCC2 expression enhancing compounds and uses thereof | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2024-08-06 | — | — | US | disclosed |
| WO-2023129553-A1 | BCL-2 INHIBITORS | Eil Therapeutics, Inc. (US) | 2023-07-06 | — | — | WO | disclosed |
| CN-109456324-B | Isoindoline or isoquinoline compounds, process for their preparation and pharmaceutical compositions containing them | 法国施维雅药厂 | 2022-04-22 | — | — | CN | disclosed |
| US-20200085817-A1 | KCC2 EXPRESSION ENHANCING COMPOUNDS AND USES THEREOF | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2020-03-19 | — | — | US | disclosed |
| CN-105408320-B | 3- (aryl or heteroaryl) methyl indol -2- ketone derivatives as cancer stem cell approach kinase inhibitor for treating cancer | 北京强新生物科技有限公司 | 2019-08-13 | — | — | CN | disclosed |
| CN-109456324-A | New isoindoline or isoquinoline compound, preparation method and the Pharmaceutical composition containing them | 法国施维雅药厂 | 2019-03-12 | — | — | CN | disclosed |
| CN-109320499-A | Pyrrole-3-carboxamide class compound and its preparation method and application | 沈阳药科大学 | 2019-02-12 | — | — | CN | disclosed |
| WO-2018217766-A1 | KCC2 EXPRESSION ENHANCING COMPOUNDS AND USES THEREOF | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2018-11-29 | — | — | WO | disclosed |
| EP-2970206-A1 | 3-(ARYL OR HETEROARYL) METHYLENEINDOLIN-2-ONE DERIVATIVES AS INHIBITORS OF CANCER STEM CELL PATHWAY KINASES FOR THE TREATMENT OF CANCER | Boston Biomedical, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014160401-A1 | 3-(ARYL OR HETEROARYL) METHYLENEINDOLIN-2-ONE DERIVATIVES AS INHIBITORS OF CANCER STEM CELL PATHWAY KINASES FOR THE TREATMENT OF CANCER | BOSTON BIOMEDICAL, INC. (US) | 2014-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200085817-A1 | KCC2 EXPRESSION ENHANCING COMPOUNDS AND USES THEREOF | MECP2, SLC1A2, GRIN2C | KDM4E 127/4885KDM6A 197/4885KDM4A 151/4885 |
| US-20250115577-A1 | BCL-2 Inhibitors | BCL2, BCL2L1, BCL2L2 | KDM4E 3326/4885KDM6A 3166/4885KDM4A 3716/4885 |
| US-12053465-B2 | KCC2 expression enhancing compounds and uses thereof | MECP2, SLC1A2, GRIN2C | KDM4E 127/4885KDM6A 197/4885KDM4A 151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.